<code id='DA3AF53794'></code><style id='DA3AF53794'></style>
    • <acronym id='DA3AF53794'></acronym>
      <center id='DA3AF53794'><center id='DA3AF53794'><tfoot id='DA3AF53794'></tfoot></center><abbr id='DA3AF53794'><dir id='DA3AF53794'><tfoot id='DA3AF53794'></tfoot><noframes id='DA3AF53794'>

    • <optgroup id='DA3AF53794'><strike id='DA3AF53794'><sup id='DA3AF53794'></sup></strike><code id='DA3AF53794'></code></optgroup>
        1. <b id='DA3AF53794'><label id='DA3AF53794'><select id='DA3AF53794'><dt id='DA3AF53794'><span id='DA3AF53794'></span></dt></select></label></b><u id='DA3AF53794'></u>
          <i id='DA3AF53794'><strike id='DA3AF53794'><tt id='DA3AF53794'><pre id='DA3AF53794'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:3
          Blue Cross Blue Shield website seen on several laptop screens. -- health business coverage from STAT
          Adobe

          A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the balance sheets of large Blue Cross Blue Shield companies, according to a STAT analysis of new federal data.

          Conversely, that same program — called “risk adjustment” — has created substantial financial burdens for startup insurers including Bright Health Group, which has now exited all health insurance markets, and Friday Health Plans, which has shut down.

          advertisement

          More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces, according to the analysis. The biggest amounts are concentrated among a few dominant Blues conglomerates.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Digital health: a case of mistaken identity

          AdobeHistoryandliteraturearerepletewithcautionarytalesonthedangersofpretendingtobesomeone—orsomethin